New & Noteworthy

June 2017

New Universal Fusion/Expression Profile

NeoGenomics Laboratories

NeoGenomics has introduced the Universal Fusion/Expression Profile, one of the first clinically validated next-generation sequencing-based profiles capable of detecting fusion transcripts and analyzing gene expression in 1,385 genes with implications in solid tumors, soft-tissue cancers, and hematologic diseases. The test covers chromosomal translocations that are not currently covered by fluorescence in situ hybridization (FISH) or for cases in which a specific molecular translocation test is not available. This test can address translocations that lead to deregulation of expression when compared to the expression of a proper normal control. The Universal Fusion/Expression Profile sequences all exon regions of the 1385 cancer genes included as part of this profile and has been validated on bone marrow, peripheral blood, FFPE, and fresh tissue.

Request More Information

Current Issue